

Malcolm D Richardson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/321960/publications.pdf>

Version: 2024-02-01

97
papers

5,586
citations

156536

32
h-index

93651

72
g-index

100
all docs

100
docs citations

100
times ranked

6490
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of self-reported environmental mould exposure on COPD outcomes. <i>Pulmonology</i> , 2023, 29, 375-384.	1.0	4
2	Invasive Aspergillosis Due to <i>Aspergillus</i> Section <i>Usti</i> : A Multicenter Retrospective Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1379-1385.	2.9	28
3	Talaromycosis in a renal transplant recipient returning from South China. <i>Transplant Infectious Disease</i> , 2021, 23, e13447.	0.7	6
4	<i>Aspergillus</i> in Indoor Environments. , 2021, , 107-115.		1
5	Molecular Epidemiology of <i>Aspergillus fumigatus</i> in Chronic Pulmonary Aspergillosis Patients. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 152.	1.5	5
6	Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect <i>Aspergillus</i> -specific antibodies in chronic pulmonary aspergillosis. <i>Respiratory Medicine</i> , 2021, 178, 106290.	1.3	10
7	Differential Proinflammatory Responses to <i>Aspergillus fumigatus</i> by Airway Epithelial Cells In Vitro Are Protease Dependent. <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 468.	1.5	11
8	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e246-e257.	4.6	167
9	Antibacterial Activity of 2-Hydroxyisocaproic Acid (HICA) Against Obligate Anaerobic Bacterial Species Associated With Periodontal Disease. <i>Microbiology Insights</i> , 2021, 14, 117863612110500.	0.9	7
10	Meteorological Factors Influence the Presence of Fungi in the Air; A 14-Month Surveillance Study at an Adult Cystic Fibrosis Center. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 759944.	1.8	6
11	Microbial contamination of heater cooler units used in extracorporeal membrane oxygenation is not aerosolized into the environment: A single-center experience. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1-3.	1.0	4
12	Biotic Environments Supporting the Persistence of Clinically Relevant Mucormycetes. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 4.	1.5	26
13	Optimising the cut-off of the Bordier <i>Aspergillus</i> IgG ELISA for the diagnosis of chronic pulmonary aspergillosis. <i>Journal of Microbiological Methods</i> , 2020, 176, 106021.	0.7	5
14	Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	17
15	Deciphering <i>Aspergillus fumigatus</i> cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3501-3509.	1.3	9
16	Evaluation of the LDBio <i>Aspergillus</i> ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis. <i>PLoS ONE</i> , 2020, 15, e0238855.	1.1	20
17	Absence of Azole Antifungal Resistance in <i>Aspergillus fumigatus</i> Isolated from Root Vegetables Harvested from UK Arable and Horticultural Soils. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 208.	1.5	6
18	The antiseptic Miramistin: a review of its comparative in vitro and clinical activity. <i>FEMS Microbiology Reviews</i> , 2020, 44, 399-417.	3.9	16

#	ARTICLE	IF	CITATIONS
19	European confederation of medical mycology expert consultâ€™An ECMM excellence center initiative. <i>Mycoses</i> , 2020, 63, 566-572.	1.8	8
20	Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1125-1132.	2.5	34
21	Positive <i>Aspergillus</i> PCR as a marker of azole resistance or subâ€™therapeutic antifungal therapy in patients with chronic pulmonary aspergillosis. <i>Mycoses</i> , 2020, 63, 376-381.	1.8	4
22	Title is missing!. , 2020, 15, e0238855.		0
23	Title is missing!. , 2020, 15, e0238855.		0
24	Title is missing!. , 2020, 15, e0238855.		0
25	Title is missing!. , 2020, 15, e0238855.		0
26	Siemens Immulite <i>Aspergillus</i> -specific IgG assay for chronic pulmonary aspergillosis diagnosis. <i>Medical Mycology</i> , 2019, 57, 300-307.	0.3	18
27	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	4.6	970
28	<i>Trichosporon japonicum</i> Fungemia and Ventricular Assist Device Infection in an Immunocompetent Patient. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz343.	0.4	9
29	Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residualAcavitation. <i>European Respiratory Journal</i> , 2019, 53, 1801184.	3.1	103
30	Evaluation of LDBio <i>Aspergillus</i> ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	36
31	National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: Evidence of sub-optimal practice. <i>Journal of Infection</i> , 2019, 79, 167-173.	1.7	27
32	Assessment of and future perspectives on standards of CARE in invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii38-ii39.	1.3	2
33	The role of occupational <i>Aspergillus</i> exposure in the development of diseases. <i>Medical Mycology</i> , 2019, 57, S196-S205.	0.3	33
34	The human lung and <i>Aspergillus</i> : You are what you breathe in?. <i>Medical Mycology</i> , 2019, 57, S145-S154.	0.3	53
35	Diagnosis and treatment of invasive fungal infections: looking ahead. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii27-ii37.	1.3	66
36	An introduction to current standards of CARE in invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii2-ii2.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1704-1712.	1.3	25
38	Exposure to <i>Aspergillus</i> in Home and Healthcare Facilities™ Water Environments: Focus on Biofilms. <i>Microorganisms</i> , 2019, 7, 7.	1.6	31
39	<i>Auxarthron alboluteum</i> related to non-dermatophytic toenail infection in Kurdistan region, Iraq: A case report. <i>Medical Mycology Case Reports</i> , 2019, 26, 53-56.	0.7	4
40	Interlaboratory Analysis of Isavuconazole Plasma Concentration Assays Among European Laboratories. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 657-664.	1.0	10
41	Diagnostic Aspects of Chronic Pulmonary Aspergillosis: Present and New Directions. <i>Current Fungal Infection Reports</i> , 2019, 13, 292-300.	0.9	14
42	Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1056-1061.	1.3	11
43	Receiver operating characteristic curve analysis of four <i>Aspergillus</i> -specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 47-51.	0.8	31
44	A systematic review of fluconazole resistance in clinical isolates of <i>Cryptococcus</i> species. <i>Mycoses</i> , 2018, 61, 290-297.	1.8	109
45	A case of pulmonary cryptococcoma due to <i>Cryptococcus gattii</i> in the United Kingdom. <i>Medical Mycology Case Reports</i> , 2018, 21, 23-25.	0.7	6
46	A Review of Onychomycosis Due to <i>Aspergillus</i> Species. <i>Mycopathologia</i> , 2018, 183, 485-493.	1.3	63
47	Sequence analysis of isolates of <i>Aspergillus</i> from patients with chronic and allergic aspergillosis reveals a spectrum of cryptic species. <i>Future Microbiology</i> , 2018, 13, 1557-1563.	1.0	8
48	Role of Serological Tests in the Diagnosis of Mold Infections. <i>Current Fungal Infection Reports</i> , 2018, 12, 127-136.	0.9	60
49	Special Issue "Fungal Burden in Different Countries", <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 80.	1.5	0
50	Transcriptome Assembly and Profiling of <i>Candida auris</i> Reveals Novel Insights into Biofilm-Mediated Resistance. <i>MSphere</i> , 2018, 3, .	1.3	151
51	Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. <i>Emerging Infectious Diseases</i> , 2018, 24, .	2.0	89
52	Prior subclinical histoplasmosis revealed in Nigeria using histoplasmin skin testing. <i>PLoS ONE</i> , 2018, 13, e0196224.	1.1	17
53	Histoplasmosis in Africa: An emerging or a neglected disease?. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006046.	1.3	125
54	Reactive oxygen: A novel antimicrobial mechanism for targeting biofilm-associated infection. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 186-191.	0.9	34

#	ARTICLE	IF	CITATIONS
55	First isolation of the pan-azole-resistant <i>Aspergillus fumigatus</i> cyp51A TR46/Y121F/T289A mutant in a UK patient. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 512-514.	1.1	12
56	Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e403-e411.	4.6	94
57	Comparative performance of <i>Aspergillus galactomannan</i> ELISA and PCR in sputum from patients with ABPA and CPA. <i>Journal of Microbiological Methods</i> , 2017, 140, 32-39.	0.7	23
58	<i>Aspergillus</i> serology: Have we arrived yet?. <i>Medical Mycology</i> , 2017, 55, 48-55.	0.3	48
59	A CONSORT analysis of randomised controlled trials for the treatment of invasive aspergillosis. <i>Medical Mycology</i> , 2016, 55, myw133.	0.3	3
60	A Case of Primary Invasive <i>Aspergillus Colitis</i> Masquerading as <i>Clostridium difficile</i> Infection. <i>Surgical Infections</i> , 2016, 17, 262-263.	0.7	2
61	Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw055.	0.4	20
62	Comparison of six <i>Aspergillus</i> -specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). <i>Journal of Infection</i> , 2016, 72, 240-249.	1.7	110
63	Antibody testing in aspergillosis—quo vadis?. <i>Medical Mycology</i> , 2015, 53, 417-439.	0.3	81
64	Successful treatment of an invasive fungal infection caused by <i>Talaromyces</i> sp. with voriconazole. <i>Medical Mycology Case Reports</i> , 2015, 8, 21-23.	0.7	4
65	Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1162-1176.	1.3	525
66	Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of <i>Aspergillus</i> quantitative PCR. <i>Mycoses</i> , 2014, 57, 69-78.	1.8	66
67	Intracellular localization of <i>Treponema denticola</i> chymotrypsin-like proteinase in chronic periodontitis. <i>Journal of Oral Microbiology</i> , 2014, 6, 24349.	1.2	12
68	Candidaemia in a tertiary hospital in Nigeria. <i>African Journal of Laboratory Medicine</i> , 2014, 3, 89.	0.2	3
69	Novel immunologic classification of aspergillosis in adult cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 560-566.e10.	1.5	180
70	In Vitro Susceptibility of <i>Aspergillus fumigatus</i> to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5778-5780.	1.4	67
71	<i>Aspergillus felis</i> sp. nov., an Emerging Agent of Invasive Aspergillosis in Humans, Cats, and Dogs. <i>PLoS ONE</i> , 2013, 8, e64871.	1.1	99
72	Î-Glucan Antigenemia Assay for the Diagnosis of Invasive Fungal Infections in Patients With Hematological Malignancies: A Systematic Review and Meta-Analysis of Cohort Studies From the Third European Conference on Infections in Leukemia (ECIL-3). <i>Clinical Infectious Diseases</i> , 2012, 54, 633-643.	2.9	260

#	ARTICLE	IF	CITATIONS
73	ADH1 expression inversely correlates with CDR1 and CDR2 in <i>Candida albicans</i> from chronic oral candidosis in APECED (APS-I) patients. <i>FEMS Yeast Research</i> , 2011, 11, 494-498.	1.1	9
74	Azole Antifungal Resistance Today: Focus on <i>Aspergillus</i> . <i>Current Infectious Disease Reports</i> , 2011, 13, 485-491.	1.3	42
75	Persistent <i>Candida albicans</i> colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2505-2513.	1.3	59
76	Azole antifungal resistance in <i>Aspergillus fumigatus</i> : 2008 and 2009. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2116-2118.	1.3	279
77	Qualified presumption of safety (QPS): a generic risk assessment approach for biological agents notified to the European Food Safety Authority (EFSA). <i>Trends in Food Science and Technology</i> , 2010, 21, 425-435.	7.8	129
78	How the host fights against <i>Candida</i> infections. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 4363.	3.0	25
79	How the host fights against <i>Candida</i> infections. <i>Frontiers in Bioscience - Scholar</i> , 2009, S1, 246-257.	0.8	13
80	<i>Candida albicans</i> isolates from APECED patients show decreased susceptibility to miconazole. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 606-608.	1.1	6
81	Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against <i>Candida albicans</i> with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 182-185.	0.8	34
82	Reduction of fluconazole susceptibility of <i>Candida albicans</i> in APECED patients due to long-term use of ketoconazole and miconazole. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 904-907.	1.5	35
83	Decreased susceptibility of <i>Candida albicans</i> to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 889-892.	1.3	49
84	Negative impact of <i>Aspergillus galactomannan</i> and DNA detection in the diagnosis of fungal rhinosinusitis. <i>Journal of Medical Microbiology</i> , 2007, 56, 1322-1327.	0.7	16
85	Metalloproteinase Function in Chronic Rhinosinusitis With Nasal Polyposis. <i>Laryngoscope</i> , 2007, 117, 638-643.	1.1	45
86	AmBisome: adds to the body of knowledge and familiarity of use. <i>Acta Biomedica</i> , 2006, 77 Suppl 4, 3-11.	0.2	0
87	Changing patterns and trends in systemic fungal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, i5-i11.	1.3	415
88	Fungi, mycological disease and pathogenic determinants. <i>British Journal of Hospital Medicine</i> , 2000, 61, 600-604.	0.3	0
89	Clinical and laboratory diagnosis. <i>British Journal of Hospital Medicine</i> , 2000, 61, 610-614.	0.3	20
90	Epidemiology. <i>British Journal of Hospital Medicine</i> , 2000, 61, 605-609.	0.3	26

#	ARTICLE	IF	CITATIONS
91	Management. British Journal of Hospital Medicine, 2000, 61, 615-619.	0.3	0
92	Panfungal PCR and Multiplex Liquid Hybridization for Detection of Fungi in Tissue Specimens. Journal of Clinical Microbiology, 2000, 38, 4186-4192.	1.8	112
93	Lipid preparations of amphotericin for the treatment of fungal infections. British Journal of Haematology, 1999, 105, 847-849.	1.2	0
94	New perspectives in the diagnosis of systemic fungal infections. Annals of Medicine, 1999, 31, 327-335.	1.5	41
95	ANTIFUNGAL THERAPY IN "BONE MARROW FAILURE". British Journal of Haematology, 1998, 100, 619-628.	1.2	45
96	Opsonic effect of C-reactive protein on phagocytosis and intracellular killing of virulent and attenuated strains of <i>Candida albicans</i> by human neutrophils. FEMS Microbiology Letters, 1991, 76, 341-344.	0.7	21
97	Diagnosis of <i>Candida</i> Infection in Tissue by Immunohistochemistry. , 0, , 1-12.		0